News
NNVC
1.482
+5.87%
0.082
NanoViricides says Phase II trial of NV-387 in ebola ‘proceeding as designed’
TipRanks · 2d ago
NanoViricides Updates Phase II Trial Of NV-387 Oral Gummies For Ebola Treatment In DRC; Reports Cautious Early Enrollment
Benzinga · 2d ago
Weekly Report: what happened at NNVC last week (0928-1002)?
Weekly Report · 2d ago
NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
Barchart · 2d ago
NanoViricides ‘actively exploring’ additional required funding
TipRanks · 09/29 12:56
NanoViricides reports FY26 EPS (41c) vs. (63c) last year
TipRanks · 09/29 12:50
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials
Barchart · 09/29 07:45
Nanoviricides Q4 EPS $(0.10), Inline
Benzinga · 09/28 21:47
NanoViricides says Phase II trial of NV-387 in ebola starts enrollment, dosing
TipRanks · 09/28 12:55
Weekly Report: what happened at NNVC last week (0921-0925)?
Weekly Report · 09/28 10:25
Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides
Barchart · 09/28 07:45
Analysts Offer Insights on Healthcare Companies: NanoViricides (NNVC) and Ionis Pharmaceuticals (IONS)
TipRanks · 09/24 13:30
Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
Barchart · 09/23 07:30
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 09/21 17:06
Weekly Report: what happened at NNVC last week (0914-0918)?
Weekly Report · 09/21 10:25
NanoViricides to begin Phase II trial of NV-387 in ebola next week
TipRanks · 09/15 13:30
NanoViricides Announces That Its Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For Current Bundibugyo Ebolavirus And Other Ebola Viruses In Democratic Republic Of Congo Is Scheduled To Begin Next Week
Benzinga · 09/15 13:28
Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in
DR Congo with 48% Crude Fatality Rate, Says NanoViricides
Barchart · 09/15 08:25
Weekly Report: what happened at NNVC last week (0907-0911)?
Weekly Report · 09/14 10:30
NanoViricides announces registration of Phase II trial of NV-387 in ebolavirus
TipRanks · 09/08 12:45
More
Webull provides a variety of real-time NNVC stock news. You can receive the latest news about Nanoviricides through multiple platforms. This information may help you make smarter investment decisions.
About NNVC
NanoViricides, Inc. is a clinical-stage company. The Company is engaged in developing a class of drugs that it calls nanoviricides, using a platform technology based on the application of nanomedicine technologies to the complex issues of viral diseases. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that has demonstrated activity in lethal lung infection animal model studies of Coronavirus (COVID), Respiratory Syncytial Virus, Influenza, Orthopoxvirus model for Smallpox and MPox, and even in a humanized mice model for Measles. It is focused on advancing Phase II clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles rash. Its NV-CoV-2 and NV-CoV-2-R are drug candidates for the treatment of COVID. Its portfolio also includes NV-HIV-1, a novel mechanism Anti-HIV Drug Candidate. Its other drug candidates include treatment for viral infections, including Dengue viruses, Ebola viruses, among others.